Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Oct 22;10(21):e39677. doi: 10.1016/j.heliyon.2024.e39677

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 4 — Combination of TNO155 and everolimus are synergistic in OSCC lines. (A) Matrix of cell viability across various combinations of TNO155 (SHP2 inhibitor) and everolimus (mTOR inhibitor) in BICR10 and PE/CA-PJ15, suggesting a synergistic effect. (B) Plot of combination index (CI) against fraction affected (Fa) of TNO155 (0.02 μM, 0.1 μM, 0.48 μM, 2.4 μM and 12 μM) and everolimus (0.0003 μM and 0.006 μM) combinations in BICR10 and PE/CA-PJ15. Only doses that are lower than single-agent IC50 is plotted here. (C) Colony formation assays at various combinations of TNO155 and everolimus showing the synergistic effect of the combinations. (D) Western blot showing the effect of the TNO155 and everolimus combinations on the phosphorylation levels of key downstream markers.